Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
63.15
-1.12 (-1.74%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
6,684,572
Open
64.17
Bid (Size)
63.16 (1)
Ask (Size)
63.35 (2)
Prev. Close
64.27
Today's Range
62.69 - 64.34
52wk Range
62.07 - 87.86
Shares Outstanding
1,253,809,440
Dividend Yield
4.75%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
June 17, 2024
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.
Via
InvestorPlace
Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
June 17, 2024
The company tested a GLP-1 drug in monkeys. But it might not actually be an obesity treatment.
Via
Investor's Business Daily
Performance
YTD
-24.14%
-24.14%
1 Month
-7.00%
-7.00%
3 Month
-13.98%
-13.98%
6 Month
-20.56%
-20.56%
1 Year
-18.74%
-18.74%
More News
Read More
Detailed Data From Gilead Halted Blood Cancer Drug Magrolimab Program Shows Higher Deaths And Side Effects
June 17, 2024
Via
Benzinga
Topics
Death
Exposures
Death
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
June 14, 2024
Via
Investor's Business Daily
What 8 Analyst Ratings Have To Say About Gilead Sciences
June 14, 2024
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
June 05, 2024
Via
Benzinga
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
June 14, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
June 13, 2024
Via
Benzinga
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
June 08, 2024
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
June 07, 2024
Via
Benzinga
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
June 06, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Should You Buy the 3 Highest-Yielding Dividend Stocks in the Nasdaq-100?
June 05, 2024
Via
The Motley Fool
The Dividend Dynamos: 7 Stocks That Will Energize Your Income Stream
June 05, 2024
Via
InvestorPlace
7 Dividend Stocks to Invest In for a Lifetime of Income
June 05, 2024
Via
InvestorPlace
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
June 05, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection
June 04, 2024
Via
Benzinga
3 Dividend Stocks That Even Ken Griffin Is Buying
June 04, 2024
Via
InvestorPlace
Large Cap BIopharmaceuticals Overview
June 03, 2024
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies
June 03, 2024
Via
Benzinga
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
June 03, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
June 03, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
June 02, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
June 01, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder Cancer
May 31, 2024
Via
Benzinga
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
May 31, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.